D
D. Fyfe
Researcher at Royal Lancaster Infirmary
Publications - 16
Citations - 1902
D. Fyfe is an academic researcher from Royal Lancaster Infirmary. The author has contributed to research in topics: Chemotherapy & Gemcitabine. The author has an hindex of 10, co-authored 15 publications receiving 1656 citations. Previous affiliations of D. Fyfe include University of Nottingham & Furness General Hospital.
Papers
More filters
Journal Article
Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.
D. R. Ferry,A Smith,J Malkhandi,D. Fyfe,P G deTakats,David E. Anderson,J Baker,David J. Kerr +7 more
TL;DR: In conclusion, quercetin can be safely administered by i.v. bolus at a dose injection and evidence of antitumor activity was seen.
Journal ArticleDOI
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial
Hugo Ford,Andrea Marshall,John Bridgewater,Tobias Janowitz,Fareeda Y. Coxon,Jonathan Wadsley,Wasat Mansoor,D. Fyfe,Srinivasan Madhusudan,Gary Middleton,Daniel Swinson,Stephen Falk,Ian Chau,David Cunningham,Paula Kareclas,Natalie Cook,Jane M Blazeby,Janet A. Dunn +17 more
TL;DR: The findings suggest that docetaxel can be recommended as an appropriate second-line treatment for patients with oesophagogastric adenocarcinoma that is refractory to treatment with platinum and fluoropyrimidine.
Journal ArticleDOI
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Anthony Maraveyas,Anthony Maraveyas,Justin Waters,Rajarshi Roy,D. Fyfe,David Propper,F. Lofts,J. Sgouros,Eric Gardiner,K. Wedgwood,Camille Ettelaie,George Bozas +11 more
TL;DR: Weight adjusted dalteparin used as primary prophylaxis for 12 weeks is safe and produces a highly significant reduction of all-type VTE during the prophyllaxis period, and the benefit is maintained after dALTeparin withdrawal although decreases with time.
Journal ArticleDOI
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
Susan J Dutton,D. R. Ferry,Jane M Blazeby,Jane M Blazeby,Haider Abbas,Asa Dahle-Smith,Wasat Mansoor,Joyce Thompson,Mark Harrison,Anirban Chatterjee,Stephen Falk,Angel Garcia-Alonso,D. Fyfe,Richard A Hubner,Tina Gamble,Lynnda Peachey,Mina Davoudianfar,Sarah Pearson,Patrick Julier,Janusz Jankowski,Rachel Kerr,Russell D. Petty +21 more
TL;DR: The use of gefitinib as a second-line treatment in oesophageal cancer in unselected patients does not improve overall survival, but has palliative benefits in a subgroup of patients with short life expectancy.
Journal ArticleDOI
Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer.
C. V. Christodoulou,David Ferry,D. Fyfe,Annie M. Young,J. Doran,T. M. T. Sheehan,Aristides G. Eliopoulos,K. Hale,J. Baumgart,G. Sass,David J. Kerr +10 more
TL;DR: The MTD of TD given on a weekly schedule is 140 mg/m2, with cumulative, but reversible creatinine and bilirubin elevation being the DLTs.